Workflow
CHALKIS(000972)
icon
Search documents
中基健康(000972) - 2022 Q1 - 季度财报
2022-04-26 16:00
Financial Performance - The company's operating revenue for Q1 2022 was CNY 24,893,658.36, a 100.00% increase compared to the same period last year when it was CNY 0.00[3] - The net profit attributable to shareholders was a loss of CNY 4,986,755.44, an improvement from a loss of CNY 19,979,751.27 in the previous year, representing a 75.01% reduction in losses[3] - The net profit for the first quarter of 2022 was -4,995,605.10 RMB, compared to -19,988,180.25 RMB in the same period last year, showing an improvement of approximately 75%[18] - The total comprehensive income attributable to the parent company was -4,986,755.44 RMB, compared to -19,979,751.27 RMB in the previous year, indicating a significant reduction in losses[19] - The basic and diluted earnings per share were both -0.0065, an improvement from -0.0259 in the prior year[19] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 42,976,551.37, compared to a negative cash flow of CNY 25,390,802.51 in the same period last year[3] - Cash inflows from operating activities totaled 66,639,447.85 RMB, a substantial increase from 149,553.82 RMB in the same period last year[20] - Cash and cash equivalents at the end of the period amounted to 63,204,247.88 RMB, up from 10,548,551.53 RMB at the end of the previous year[21] - The company's cash and cash equivalents increased to CNY 63,204,247.88 from CNY 20,517,341.41 at the beginning of the year, representing a growth of approximately 207.5%[13] Assets and Liabilities - Total assets at the end of the reporting period were CNY 705,638,598.38, reflecting a 3.42% increase from CNY 682,336,138.44 at the end of the previous year[3] - Total liabilities rose to CNY 630,002,798.51 from CNY 601,705,050.46, an increase of approximately 4.7%[15] - The total equity attributable to shareholders decreased to CNY 70,537,058.61 from CNY 75,523,652.38, a decline of about 6.5%[16] Operating Costs and Expenses - Total operating costs for Q1 2022 amounted to CNY 30,042,866.00, an increase from CNY 20,017,428.02 in the previous year[17] - The company reported operating expenses of 23,662,896.48 RMB, slightly lower than 25,540,356.33 RMB in the previous year[20] - The company's management expenses decreased by 63.89% to CNY 6,739,952.29 from CNY 18,666,259.97 in the previous year due to reduced operational costs[7] Taxation and Subsidies - The company reported a 1820.85% increase in taxes and surcharges, amounting to CNY 116,403.27, compared to CNY 6,060.00 in the previous year[7] - The company received government subsidies amounting to CNY 89,218.29, marking a 100.00% increase from CNY 0.00 in the previous year[7] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,338[10] Inventory and Receivables - Accounts receivable decreased to CNY 126,855,321.23 from CNY 135,604,961.65, a decline of about 6.0%[13] - Inventory decreased to CNY 151,678,614.40 from CNY 160,812,447.35, reflecting a reduction of approximately 5.7%[14] Research and Development - The company incurred research and development expenses of CNY 458.49, with no expenses reported in the same period last year[17] Other Information - The company did not report any significant new product developments or market expansions during this quarter[22]
中基健康(000972) - 2021 Q4 - 年度财报
2022-03-25 16:00
Financial Performance - The company's operating revenue for 2021 was approximately ¥174.45 million, representing a 659.61% increase compared to ¥22.97 million in 2020[19]. - The net profit attributable to shareholders for 2021 was a loss of approximately ¥100.52 million, an improvement from a loss of ¥265.89 million in 2020[19]. - The net cash flow from operating activities for 2021 was a negative ¥188.67 million, compared to a negative ¥9.89 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥682.34 million, an increase of 17.14% from ¥582.51 million at the end of 2020[19]. - The net assets attributable to shareholders decreased by 57.10% to approximately ¥75.52 million at the end of 2021 from ¥176.04 million at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.13, an improvement from -¥0.34 in 2020[19]. - The weighted average return on net assets for 2021 was -79.92%, a decrease of 6.13 percentage points from -86.05% in 2020[19]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[75]. - The company reported a total revenue of 11,700 million in 2021, with a significant increase compared to the previous year[76]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year increase of 20%[82]. - The total comprehensive loss for 2021 was CNY -100,580,101.65, compared to CNY -266,724,598.87 in 2020, indicating a reduction of approximately 62.3%[197]. Operational Highlights - The company produced over 58,000 tons of bulk tomato sauce during the production period from August 8 to September 30, 2021[31]. - The company resumed production of high-value tomato lycopene health products to optimize its product structure[34]. - The company maintained a seasonal production cycle for fresh tomatoes, with the harvesting period from early August to the end of September[34]. - The company has fully restored its tomato industry production, optimizing the product structure to include high-value tomato lycopene health products and small-packaged tomato sauce[64]. - The company plans to produce 80,000 tons of large-packaged tomato sauce and 200,000 bottles of lycopene in the upcoming year[63]. - The company has signed a contract for the leasing of tomato harvesting machines to alleviate financial pressure and reduce costs[30]. - The company has engaged in multiple investor communications, receiving over 300 inquiries via phone and 107 written inquiries during the reporting period[67]. Strategic Initiatives - The company plans to enhance its market-oriented operational mechanism and improve cost management to boost profitability in the tomato industry[29]. - The company is focusing on improving its corporate governance structure and exploring long-term incentive mechanisms to ensure sustainable development[64]. - The company is actively exploring market expansion opportunities to enhance its core competitiveness and profitability[65]. - The company is committed to utilizing capital market financing and restructuring effects to increase its resilience and create new profit growth points[65]. - The company has established a post-doctoral research workstation to enhance its technological innovation capabilities[32]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[80]. Governance and Management - The company has established a complete independent governance structure, ensuring operational independence from its controlling shareholders[71]. - The company is focused on maintaining a transparent remuneration policy for its executives[90]. - The total remuneration for directors, supervisors, and senior management was 1.7465 million yuan (including tax) as of December 31, 2021[90]. - The company has a structured salary management system for determining the remuneration of its directors and senior management[90]. - The company has appointed new board members with diverse backgrounds and experiences to strengthen its management team[79]. - The company has implemented a training mechanism for employees, focusing on various levels of management and general staff[102]. Risks and Challenges - The company has faced continuous operating capability uncertainties as indicated in the audit report for the recent year[19]. - The company is facing risks related to adverse weather conditions in Xinjiang, which could impact tomato yield and quality, thus affecting production and operational stability[65]. - The audit opinion highlighted a significant uncertainty regarding the company's ability to continue as a going concern, raising concerns about its financial stability[172]. - The company is closely monitoring the ongoing legal proceedings and their potential impacts on its operations[132]. Legal and Compliance - The company has not faced any penalties from securities regulatory authorities for its current and recently departed directors, supervisors, and senior management[88]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[120]. - The company has initiated a lawsuit against the execution objection, with the court ruling on May 20, 2020, rejecting the plaintiff's request for 123,970,926.36 yuan[128]. - The company has frozen bank accounts with a total amount of 12,739.71 yuan, including 9,377.65 yuan at China Merchants Bank and 3,362.29 yuan at Xinjiang Urumqi Rural Commercial Bank[130]. Future Outlook - The company projects a revenue growth of 10% for the next fiscal year, targeting 1.65 billion in total revenue[75]. - New product launches are expected to contribute an additional 200 million in revenue in the upcoming year[75]. - The company aims to turn losses into profits as part of its operational goals for 2022[63]. - The company anticipates a positive outlook for future performance, driven by strategic growth initiatives and market expansion efforts[76].
中基健康(000972) - 2020 Q1 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for Q1 2020 was ¥2,758,230.08, a decrease of 96.99% compared to ¥91,484,302.22 in the same period last year[8] - The net profit attributable to shareholders was -¥13,041,004.34, representing a 45.43% increase in losses compared to -¥8,966,936.17 in the previous year[8] - The net profit decreased by 44.47% to -¥13,053,465.20 from -¥9,035,125.01, reflecting reduced income and increased expenses[15] - The net loss for Q1 2020 was CNY 13,053,465.20, compared to a net loss of CNY 9,035,125.01 in Q1 2019, reflecting an increase in losses of approximately 44%[35] - The total comprehensive income for the parent company in Q1 2020 was -¥13,041,004.34, compared to -¥8,966,936.17 in Q1 2019, indicating a significant decline in overall performance[36] - Basic and diluted earnings per share for Q1 2020 were both -¥0.0169, worsening from -¥0.0116 in Q1 2019[36] Cash Flow and Liquidity - The net cash flow from operating activities was -¥4,790,684.39, which is a 63.16% improvement from -¥13,002,306.18 in the same period last year[8] - Cash and cash equivalents decreased by 66.27% to ¥27,197,614.66 from ¥80,644,820.58 due to loan repayments[15] - Cash received from sales dropped by 99.98% to ¥4,000.00 from ¥21,623,066.04, indicating no product sales during the quarter[15] - The company's cash and cash equivalents dropped from CNY 68,436,735.75 at the end of 2019 to CNY 14,980,430.44 by March 31, 2020, a decrease of about 78%[30] - The company reported a total cash outflow from financing activities of -¥48,005,077.36 in Q1 2020, compared to -¥16,172,991.27 in the same period last year, indicating increased cash outflows related to financing[44] - The cash received from other operating activities was 20,175.53 yuan, a notable increase from the previous period[45] Assets and Liabilities - The total assets at the end of the reporting period were ¥674,451,770.44, down 8.89% from ¥740,282,440.65 at the end of the previous year[8] - The total liabilities decreased from CNY 292,346,652.15 at the end of 2019 to CNY 239,569,447.14 by March 31, 2020, a reduction of about 18%[30] - The total equity attributable to shareholders decreased from CNY 441,936,607.51 at the end of 2019 to CNY 428,895,603.17 by March 31, 2020, a decline of approximately 3%[30] Operating Costs and Expenses - Operating costs decreased by 96.18% to ¥3,347,191.68 from ¥87,733,345.57, also due to factory shutdowns[15] - Management expenses increased by 35.12% to ¥11,382,896.18 from ¥8,424,348.49 due to costs associated with the shutdown[15] - The company incurred sales expenses of ¥20,832.67 in Q1 2020, up from ¥2,220.00 in Q1 2019, indicating increased costs associated with sales efforts[38] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,804[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of the shares[10] Other Information - The company reported no non-recurring gains or losses during the reporting period[8] - The company did not undergo an audit for the first quarter report[48] - The company has not applied new revenue and leasing standards for the current reporting period[48]
中基健康(000972) - 2020 Q3 - 季度财报
2021-10-28 16:00
Financial Performance - Operating revenue for the reporting period was CNY 42,964,683.12, an increase of 5,271.56% year-on-year[8] - Net profit attributable to shareholders of the listed company was CNY 2,667,106.83, with a year-to-date loss of CNY 42,077,086.68[8] - Basic earnings per share for the reporting period were CNY 0.003, compared to a loss of CNY 0.0546 in the same period last year[8] - The weighted average return on net assets was 0.61%, an increase of 1.76 percentage points year-on-year[8] - The company reported a net loss attributable to shareholders of ¥42,077,086.68, a decrease of 284.06% from a profit of ¥22,860,511.96 in the previous period[15] - The total comprehensive income decreased by 285.52% to -¥42,112,313.51 from ¥22,699,015.33, reflecting the overall financial downturn[15] - The company reported a net loss in retained earnings, increasing from CNY -1,437,437,657.71 to CNY -1,479,549,971.22, indicating a worsening of approximately 2.9%[33] - The company reported a net loss of CNY 42,112,313.51 for Q3 2020, compared to a net profit of CNY 22,699,015.33 in the same period last year, indicating a significant decline in profitability[48] - The total profit for the period was CNY -42,158,034.04, contrasting with a profit of CNY 23,365,182.52 in the prior year, highlighting a drastic shift in financial performance[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 669,410,187.63, a decrease of 9.57% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company were CNY 399,819,294.00, down 9.53% from the previous year[8] - Current assets decreased from CNY 336,301,718.81 to CNY 298,480,266.42, a reduction of about 11.3%[30] - Total liabilities decreased from CNY 292,346,652.15 to CNY 263,554,151.72, a decline of about 9.8%[32] - Non-current assets decreased from CNY 403,980,721.84 to CNY 370,929,921.21, a decline of about 8.2%[31] - The total equity attributable to shareholders decreased from CNY 441,936,607.51 to CNY 399,819,294.00, a reduction of approximately 9.5%[33] Cash Flow - The company reported a net cash flow from operating activities of CNY -1,669,475.90 for the reporting period[8] - The company's cash and cash equivalents decreased by 66.96% to ¥26,646,992.28 from ¥80,644,820.58 due to business transformation and debt repayment[15] - Cash flow from operating activities showed a net outflow of CNY -2,897,879.20, a significant decrease from a net inflow of CNY 54,803,106.71 in the same quarter last year[53] - The company received cash related to operating activities of ¥50,001,448.33, an increase of 91.26% from ¥26,143,150.72, indicating improved cash flow from operations[16] - The cash flow from investment activities showed a net outflow of -5,008,000.00 CNY, contrasting with a net inflow of 68,935,364.09 CNY in the previous period[58] - Cash flow from financing activities resulted in a net outflow of -48,005,077.36 CNY, compared to -120,469,078.30 CNY in the previous period, indicating improved cash management[58] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,141[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of the shares[11] Business Transformation and Strategy - The company plans to issue shares to raise funds for the modernization of traditional Chinese medicine and emergency medical supplies production, which will change its main business focus[17] - The company is focusing on market expansion and new product development as part of its strategic initiatives, although specific details were not disclosed in the report[48] - The company has not engaged in any securities or derivative investments during the reporting period[19][20] Operational Costs and Expenses - The total operating costs for the year-to-date were 70,506,467.43, compared to 232,818,833.74 in the previous year[47] - Management expenses increased to CNY 36,853,759.11 from CNY 29,580,073.59, indicating rising operational costs[48] - Research and development expenses for the third quarter amounted to 10,179,080.15, indicating ongoing investment in innovation[40] - Research and development expenses amounted to CNY 11,721,700.00, indicating ongoing investment in innovation despite financial losses[48] Other Financial Metrics - The company recorded other income of CNY 178,736.58, which was lower than the previous year's CNY 374,068.77, suggesting reduced ancillary income sources[48] - The company reported a credit impairment loss of -5,498,845.88 for the third quarter, reflecting challenges in asset quality[40] - The company incurred a credit impairment loss of CNY -16,521,669.99, which negatively impacted overall profitability[48] - There were no non-recurring gains or losses reported during the reporting period[8] Future Reporting and Standards - The company has not yet audited the third-quarter report, which may affect the reliability of the financial data presented[59] - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[59]
中基健康(000972) - 2021 Q1 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for Q1 2021 was 0.00, a decrease of 100.00% compared to 2,758,230.08 in the same period last year[8] - The net profit attributable to shareholders was -19,979,751.27, representing an increase of 53.21% from -13,041,004.34 year-on-year[8] - The basic earnings per share were -0.0259, a decline of 53.25% from -0.0169 in the same period last year[8] - The total profit loss increased by 53.13% to ¥-19,988,180.25 compared to ¥-13,053,465.20 in the previous year, reflecting the ongoing transformation and production halt[15] - The net profit for Q1 2021 was a loss of CNY 19,988,180.25, compared to a loss of CNY 13,053,465.20 in the same period last year, indicating an increase in losses of about 53.5%[39] - The total operating costs for Q1 2021 were CNY 20,017,428.02, an increase from CNY 15,920,524.82 in the previous year, representing a growth of approximately 25.8%[38] Cash Flow and Liquidity - The net cash flow from operating activities was -25,390,802.51, an increase of 430.00% compared to -4,790,684.39 in the previous year[8] - The cash inflow from operating activities totaled CNY 149,553.82 in Q1 2021, a decrease from CNY 733,296.72 in the previous year[45] - Total cash outflow from operating activities amounted to 25,540,356.33 CNY, while cash inflow was only 1,581,660.56 CNY, resulting in a negative cash flow situation[49] - The ending cash and cash equivalents balance decreased to 10,548,551.53 CNY from 37,016,403.17 CNY at the beginning of the period, indicating a cash depletion of 26,467,851.64 CNY[47] - The company’s cash and cash equivalents decreased significantly from CNY 366,012.44 to CNY 16,884.87, a decline of approximately 95.4%[32] - The company’s cash and cash equivalents decreased by 71.32% to ¥10,613,891.89 from ¥37,007,442.78 due to a transformation and production halt[15] Assets and Liabilities - The total assets at the end of the reporting period were 562,832,228.58, down 3.38% from 582,505,841.85 at the end of the previous year[8] - The total liabilities increased slightly from CNY 401,294,652.22 to CNY 401,609,219.20, an increase of about 0.8%[31] - The company’s total equity decreased from CNY 181,211,189.63 to CNY 161,223,009.38, a decline of approximately 11%[32] - The total current liabilities increased from CNY 245,683,431.85 to CNY 245,963,265.50, an increase of about 0.1%[31] - The total non-current assets slightly increased from CNY 361,212,417.84 to CNY 362,306,880.74, an increase of about 0.3%[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,156[10] - The top shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of shares[10] Operational Changes - The company is currently undergoing a transformation and production halt, impacting all major financial metrics significantly[15] - Management expenses increased by 63.99% to ¥18,666,259.97, attributed to fixed asset depreciation[15] - The company reported no non-recurring gains or losses during the reporting period[8] - The company did not report any cash inflow from investment activities, highlighting a lack of investment recovery during the quarter[50] - The company reported a credit impairment loss of CNY 25,000.00 in Q1 2021, compared to no such loss in the previous year[38] Tax and Financial Expenses - The company reported a 260.97% increase in tax payments to ¥9,401,699.46, due to tax liabilities from December 2020[17] - The financial expenses for Q1 2021 were CNY 1,345,108.05, up from CNY 1,072,145.61 in the previous year, indicating an increase of about 25.3%[38]
中基健康(000972) - 2021 Q3 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for the third quarter was ¥4,233,801.45, a decrease of 90.15% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥8,548,581.94, with a year-to-date loss of ¥54,849,067.67, representing a 30.35% increase in losses year-on-year[4] - Total operating revenue for the period was CNY 7,359,465.17, a decrease of 83.93% compared to CNY 45,786,377.20 in the previous period[20] - The net profit for Q3 2021 was a loss of CNY 54,876,089.09, compared to a loss of CNY 42,112,313.51 in the previous year, reflecting a worsening financial position[22] - The total comprehensive income for the period was a loss of CNY 54,876,089.09, compared to a loss of CNY 42,112,313.51 in the same quarter last year[22] - Basic and diluted earnings per share were both reported at CNY -0.0711, compared to CNY -0.0546 in the previous year[22] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was -¥260,820,543.21, an increase of 8,900.39% compared to the previous year[4] - Cash received from operating activities decreased by 75.85% to ¥12,072,906.77 compared to the previous year[8] - The cash flow from operating activities showed a net outflow of CNY 260,820,543.21, compared to a smaller outflow of CNY 2,897,879.20 in the same quarter last year[25] - The company reported a cash inflow from financing activities of CNY 275,587,666.68, a significant increase from a cash outflow of CNY 48,005,077.36 in the previous year[26] - The company’s cash and cash equivalents at the end of the period totaled CNY 50,547,571.13, an increase from CNY 26,646,992.28 at the end of the previous year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥863,303,440.02, an increase of 48.21% from the end of the previous year[4] - The company reported a total liability of CNY 736,968,339.48, compared to CNY 401,294,652.22 in the previous year[18] - Current assets totaled CNY 534,939,116.31, significantly up from CNY 221,293,424.01 at the end of 2020[16] - Total current liabilities rose to CNY 583,356,969.11 from CNY 245,683,431.85[18] - The company's equity attributable to shareholders decreased by 31.16% to ¥121,194,771.79 compared to the end of the previous year[4] - The company’s equity attributable to shareholders decreased to CNY 121,194,771.79 from CNY 176,043,839.46[18] Shareholder Information - The company had a total of 30,017 common shareholders at the end of the reporting period[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., holds 16.18% of the shares[10] Research and Development - Research and development expenses were reduced to ¥0.00 from ¥11,721,700.00 in the previous year, indicating a 100% decrease[7] - The company did not report any research and development expenses in Q3 2021, compared to CNY 11,721,700.00 in the same period last year[21] Operational Changes - The company reported a significant increase in accounts payable, which rose by 139.16% to ¥77,658,590.11 due to the resumption of production[7] - The total operating costs amounted to CNY 54,662,671.06, with operating costs specifically at CNY 7,873,335.63, down from CNY 17,470,147.34 year-over-year[21] - The company’s management expenses rose to CNY 40,941,641.91, up from CNY 36,853,759.11 year-over-year[21] - Inventory reached CNY 290,514,718.50, indicating a new addition as there was no inventory reported in the previous period[16] Legal and Regulatory Issues - The company is facing a court-ordered freeze on dividends amounting to CNY 123,970,926.36 for a period of three years[12]
中基健康(000972) - 2021 Q2 - 季度财报
2021-08-26 16:00
Financial Performance - The company's operating revenue for the first half of 2021 was ¥3,125,663.72, representing a 10.77% increase compared to ¥2,821,694.08 in the same period last year[21]. - The net profit attributable to shareholders was -¥46,300,485.73, slightly worse than -¥44,744,193.51 in the previous year[21]. - The net cash flow from operating activities was -¥18,531,697.98, compared to -¥6,808,897.15 in the same period last year[21]. - Total assets decreased by 7.53% to ¥538,653,747.66 from ¥582,505,841.85 at the end of the previous year[21]. - The net assets attributable to shareholders decreased by 26.30% to ¥129,743,353.73 from ¥176,043,839.46 at the end of the previous year[21]. - The weighted average return on net assets was -30.28%, an increase of 19.62 percentage points compared to -10.66% in the previous year[21]. - The company reported a net profit of -28.8 million for the period, indicating ongoing financial challenges[45]. - The company reported a total comprehensive loss of -46,321,199.04 CNY for the first half of 2021, compared to -44,769,204.53 CNY in the same period last year, representing an increase in losses of about 3.5%[113]. - The company's operating profit for the first half of 2021 was -46,982,640.85 CNY, compared to -44,833,816.31 CNY in the same period of 2020, indicating a decline of approximately 4.8%[113]. - The total liabilities as of June 30, 2021, amounted to CNY 403,763,757.07, slightly up from CNY 401,294,652.22 at the end of 2020[106]. Cash Flow and Liquidity - Cash and cash equivalents decreased significantly from CNY 37,007,442.78 to CNY 15,530,753.63, representing a decline of approximately 58.0%[103]. - The cash flow from operating activities for the first half of 2021 was -18,531,697.98 CNY, worsening from -6,808,897.15 CNY in the first half of 2020[120]. - The company had a cash and cash equivalents balance of 15,530,253.63 CNY at the end of the first half of 2021, down from 24,707,597.07 CNY at the end of the same period in 2020, a decrease of approximately 37.1%[121]. - The company reported a total cash outflow from investing activities of 214,751.73 yuan, compared to 5,003,000.00 yuan in the first half of 2020, reflecting a significant reduction in investment spending[124]. - The company's cash flow from operating activities showed a significant decrease in cash inflow from 488,111.74 yuan in the first half of 2020 to 10,259,380.76 yuan in the first half of 2021[123]. Operational Strategy and Future Plans - The company has initiated the recovery of tomato production and is organizing production work to gradually restore factory output and cost plans[28]. - The company plans to gradually restore production in its tomato industry, with expectations of improved market conditions for tomato sauce in the future[47]. - The company aims to optimize its product structure by focusing on high-value tomato lycopene health products[47]. - The company is committed to improving its capital operation efficiency and exploring long-term incentive mechanisms for employees[48]. - The company plans to enhance resource integration and reduce burdens by leasing assets, specifically through a contract for 87 tomato harvesters[80]. - The company aims to enhance its talent training system and recruitment mechanisms to improve management levels and overall employee quality[156]. Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 31,341[90]. - The largest shareholder, Xinjiang Production and Construction Corps, holds 16.18% of the shares, totaling 124,769,223 shares[90]. - The total number of shares remains at 771,283,579, with no changes reported[88]. - The total equity attributable to the parent company decreased to CNY 129,743,353.73 from CNY 176,043,839.46 at the end of 2020, reflecting a decline of approximately 26.3%[106]. - The company reported a total of CNY 540,843,097.79 in other receivables as of June 30, 2021, down from CNY 546,630,845.03 at the end of 2020[109]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding its future plans and projections[5]. - The company has faced significant operational risks due to adverse weather conditions affecting tomato production[46]. - The company has fulfilled all commitments made by its actual controllers, shareholders, and related parties during the reporting period[62]. - There are no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[63]. - The company has no violations regarding external guarantees during the reporting period[64]. - The semi-annual financial report has not been audited[65]. Corporate Governance and Social Responsibility - The company is committed to enhancing the leadership role of the Party in state-owned enterprises and improving corporate governance to ensure sustainable development[155]. - The company actively participates in social responsibility initiatives, including poverty alleviation and supporting local agricultural development[58]. - The company emphasizes environmental protection and energy conservation as part of its operational strategy[58].
中基健康(000972) - 2021 Q1 - 季度财报
2021-04-29 16:00
Financial Performance - The company's operating revenue for Q1 2021 was 0.00, a decrease of 100.00% compared to 2,758,230.08 in the same period last year[8] - The net profit attributable to shareholders was -19,979,751.27, representing an increase in loss of 53.21% from -13,041,004.34 year-on-year[8] - The net cash flow from operating activities was -25,390,802.51, which is a significant decline of 430.00% compared to -4,790,684.39 in the previous year[8] - The basic earnings per share were -0.0259, a decrease of 53.25% from -0.0169 in the same period last year[8] - The total profit loss increased by 53.13% to ¥-19,988,180.25 compared to ¥-13,053,465.20 in the previous year, indicating ongoing financial challenges[15] - The total comprehensive loss for Q1 2021 was CNY 19,988,180.25, compared to a loss of CNY 13,053,465.20 in the same period last year, marking an increase in losses of approximately 53.5%[40] Assets and Liabilities - The total assets at the end of the reporting period were 562,832,228.58, down 3.38% from 582,505,841.85 at the end of the previous year[8] - The net assets attributable to shareholders decreased by 11.35% to 156,064,088.19 from 176,043,839.46 at the end of the previous year[8] - Total liabilities increased slightly from CNY 401,294,652.22 to CNY 401,609,219.20, reflecting a growth of about 0.8%[31] - The company's total equity decreased from CNY 181,211,189.63 to CNY 161,223,009.38, representing a decline of approximately 11%[32] Cash Flow - The company's cash and cash equivalents decreased by 71.32% to ¥10,613,891.89 from ¥37,007,442.78 due to a transformation and production halt[15] - Cash inflows from operating activities totaled CNY 149,553.82, a significant decrease from CNY 733,296.72 in the previous year[45] - The net cash flow from investing activities was -732,049.14 CNY, with no cash inflow recorded from investment activities[46] - The net cash flow from financing activities was -344,999.99 CNY, compared to -48,005,077.36 CNY in the previous period, showing a reduction in cash outflow related to financing[47] - The ending balance of cash and cash equivalents was 10,548,551.53 CNY, down from 26,161,078.33 CNY in the previous period, indicating a decrease in liquidity[47] Operational Challenges - Operating revenue dropped to ¥0.00, a 100% decrease compared to ¥2,758,230.08 in the previous year, as the company is in a transformation and production halt[15] - Management expenses increased by 63.99% to ¥18,666,259.97, primarily due to fixed asset depreciation[15] - The company reported no non-recurring gains or losses during the reporting period[8] - The company incurred a credit impairment loss of CNY 25,000.00, compared to no losses in the previous year[39] - The company has been actively communicating with investors, responding to over 50 inquiries regarding production and operational status during the reporting period[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,156[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., holds 16.18% of the shares[10] Miscellaneous - The company has not engaged in any securities or derivative investments during the reporting period[20][21] - The company did not report any cash inflow from investment activities, indicating a lack of new investments during the period[48] - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[51]
中基健康(000972) - 2020 Q4 - 年度财报
2021-04-22 16:00
Financial Performance - The company's operating revenue for 2020 was ¥22,966,067.61, a decrease of 89.23% compared to ¥213,188,826.11 in 2019[17]. - The net profit attributable to shareholders for 2020 was -¥265,892,768.05, compared to a profit of ¥4,975,779.02 in 2019[17]. - The net profit after deducting non-recurring gains and losses was -¥129,860,055.27, a 14.65% increase in losses compared to -¥113,681,230.79 in 2019[17]. - The net cash flow from operating activities was -¥9,889,117.18, a significant decline from ¥142,656,995.36 in 2019[17]. - The basic earnings per share for 2020 was -¥0.34, compared to ¥0.01 in 2019[17]. - The total assets at the end of 2020 were ¥582,505,841.85, down from ¥740,282,440.65 at the end of 2019[17]. - The net assets attributable to shareholders decreased by 60.17% to ¥176,043,839.46 from ¥441,936,607.51 in 2019[17]. - The company reported a weighted average return on net assets of -86.05% for 2020, a decrease of 87.18 percentage points compared to the previous year[17]. - The company reported a net profit attributable to shareholders of -265.89 million yuan for 2020, with total net assets of ¥176,043,839.46[38]. - The company reported a net profit of -266,724,598.87 CNY, with a net profit attributable to shareholders of -265,892,768.05 CNY, indicating significant financial challenges[92]. Operational Challenges - The company has been warned of delisting risk due to negative net profit and operating revenue below ¥100 million[5]. - The company faced significant operational challenges, including insufficient self-financing capacity and a shortage of operating funds due to continuous losses[39]. - The rental service sector showed a gross margin of -59.27%, indicating a significant increase in operating costs compared to the previous year[45]. - The company’s manufacturing segment reported zero revenue in 2020, down from ¥192,504,754.63 in 2019, indicating a complete halt in this area[42]. - The company has not proposed any cash dividend distribution plans for the past three years, indicating a focus on reinvestment[88]. Strategic Initiatives - The company plans to issue stocks to raise funds for the construction of a medical emergency material production base in Xinjiang, aiming to enhance its capabilities in the pharmaceutical and health technology sectors[29]. - The company is focusing on transforming its business towards pharmaceutical technology and health technology, aiming to create new profit growth points[29]. - The company aims to enhance its core competitiveness in the medical protection industry by improving product quality and expanding into international markets[32]. - The company plans to establish a 500-acre emergency medical supplies industrial park, aiming to complete the overall layout design in 2021 and initiate the construction of production facilities[77]. - The company intends to enhance its research and development capabilities by increasing investment and forming strategic alliances with universities and research institutions for innovative drug development[78]. Market and Industry Trends - The company anticipates a significant growth in the emergency medical materials sector, with an expected increase exceeding 1000% in 2020 due to the COVID-19 pandemic[32]. - The company is focused on developing emergency medical supplies production to improve its capacity for emergency medical reserves in Xinjiang and nationwide[79]. - The company reported a steady growth in the Chinese herbal medicine industry, with production reaching 424.3 million tons in 2017, up from 400.2 million tons in 2016[75]. - The market size of the Chinese herbal medicine industry expanded to 746 billion yuan by 2017, up from 600 billion yuan in 2014[75]. Governance and Management - The company has maintained a stable management team, with all current directors and executives holding 0 shares at the beginning and end of the reporting period, except for the CFO[141]. - The company is committed to transparency in its governance, as evidenced by the detailed reporting of management changes and shareholding status[142]. - The company has established a complete independent financial department with its own accounting system and tax obligations[170]. - The company has a well-structured corporate governance system that complies with relevant laws and regulations, with no significant discrepancies identified[169]. - The company has not reported any significant changes in shareholding among its independent directors during the reporting period[141]. Audit and Compliance - The audit firm Zhongxing Caiguanghua issued a non-standard audit report, highlighting significant uncertainties regarding the company's ability to continue as a going concern[92]. - The internal control audit report confirmed that the company maintained effective financial reporting internal controls as of December 31, 2020, with no major deficiencies identified[185]. - The audit opinion issued by Zhongxing Caiguanghua Accounting Firm was a qualified opinion with a paragraph on going concern uncertainty, highlighting potential doubts about the company's ability to continue operations[189]. - The audit identified significant risks related to potential misstatements due to fraud or error, necessitating thorough evaluation and testing of internal controls[196]. Employee and Workforce - The company employed a total of 52 staff members, with 21 being technical personnel and 7 financial personnel[163]. - The educational background of employees included 8 with postgraduate degrees, 17 with bachelor's degrees, and 18 with associate degrees[164]. - The company has established a fair and transparent performance evaluation standard and incentive mechanism for employee performance assessment and rewards[166]. - The company has implemented a training and re-education mechanism, focusing on enhancing the capabilities and qualities of all employees through a combination of internal and external training[166]. Shareholder Information - The total number of unrestricted shares is 771,283,579, representing 100.00% of the total shares[127]. - The total number of shareholders at the end of the reporting period is 33,081[129]. - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., holds 16.18% of the shares, totaling 124,769,223 shares[129]. - The company has not reported any share buyback progress or changes in share transfer situations[127].
中基健康(000972) - 2020 Q3 - 季度财报
2020-10-28 16:00
Financial Performance - Operating revenue for the reporting period was ¥42,964,683.12, an increase of 5,271.56% compared to the same period last year[9]. - Net profit attributable to shareholders of the listed company was ¥2,667,106.83, with a year-to-date loss of ¥42,077,086.68[9]. - Basic earnings per share for the reporting period were ¥0.003, compared to a loss of ¥0.0546 in the same period last year[9]. - The weighted average return on net assets was 0.61%, an increase of 1.76 percentage points year-on-year[9]. - The company reported a net loss attributable to shareholders of ¥42,077,086.68, a decrease of 284.06% from a profit of ¥22,860,511.96 in the previous period[16]. - The total comprehensive income decreased by 285.52% to a loss of ¥42,112,313.51 from a profit of ¥22,699,015.33 in the previous period[16]. - The company reported a net loss of CNY 42,112,313.51 for Q3 2020, compared to a net profit of CNY 22,699,015.33 in the same period last year, indicating a significant decline in profitability[49]. Assets and Liabilities - Total assets at the end of the reporting period were ¥669,410,187.63, a decrease of 9.57% compared to the end of the previous year[9]. - Net assets attributable to shareholders of the listed company were ¥399,819,294.00, down 9.53% year-on-year[9]. - Total liabilities decreased from CNY 292,346,652.15 to CNY 263,554,151.72, a decline of about 9.8%[33]. - The company’s non-current assets decreased from CNY 403,980,721.84 to CNY 370,929,921.21, a reduction of approximately 8.2%[32]. - The company’s accounts payable increased by 131.15% to ¥64,724,799.20 from ¥28,000,855.36, indicating outstanding payments for outsourced services[16]. Cash Flow - The company reported a net cash flow from operating activities of -¥1,669,475.90 for the reporting period[9]. - Cash received from sales of goods and services dropped by 86.31% to ¥14,893,861.00 from ¥108,777,383.74, reflecting the impact of business transformation[17]. - The company generated CNY 64,895,309.33 in cash inflows from operating activities, down from CNY 135,028,231.07 in the previous year[54]. - The net cash flow from operating activities was -63,094,886.90 CNY, compared to -36,717,135.48 CNY in the previous period, indicating a significant increase in cash outflow[59]. - The company reported a total cash outflow of 86,593,897.30 CNY from operating activities, which is significantly higher than the previous period's outflow of 53,723,430.56 CNY[59]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,141[11]. - The top ten shareholders held a combined 42.70% of the company's shares, with the largest shareholder holding 16.18%[12]. Business Transformation and Strategy - The company plans to issue shares to raise funds for the modernization of traditional Chinese medicine and emergency medical supplies production, which will change its main business focus[18]. - The company is focusing on market expansion and new product development as part of its strategic initiatives[41]. Research and Development - Research and development expenses for Q3 2020 were CNY 10,179,080.15, indicating ongoing investment in innovation[41]. - Research and development expenses amounted to CNY 11,721,700.00, reflecting the company's commitment to innovation despite financial losses[49]. Audit and Verification - The report was not audited, indicating that the figures presented may be subject to further verification[60].